The article examines Jeff Dean's resignation, Hassabis's shift to DeepMind chairman, rumors that he wanted to leave but was retained by Google, and how these moves reflect a broader strategic pivot of DeepMind toward product‑focused Gemini work and away from its independent research roots.
The article debunks the popular claim that AI should be limited to simple, repetitive work, showing that large‑model AI differs from traditional automation by understanding complex information, processing massive codebases, solving scientific problems like protein folding, and outperforming human experts across many domains.
DeepMind has dissolved the independent AlphaFold team that earned a Nobel Prize, reallocating its researchers to Gemini, AI programming, genomics and other projects, while key members depart for Anthropic, prompting questions about the future of Hassabis and Google’s AI strategy.
In a deep interview, AlphaFold’s core developer John Jumper explains how domain‑specific engineering, extensive ablation studies, and a hybrid Evoformer‑IPA architecture—not sheer compute—enabled protein‑folding breakthroughs, while distinguishing AI’s roles in prediction, control, and human‑in‑the‑loop understanding.
John Jumper, the Nobel‑winning architect of AlphaFold, left DeepMind after nine years to join Anthropic, sparking a talent exodus that highlights an accelerating AI‑driven competition among Anthropic, OpenAI and DeepMind to rewrite life‑science research.
ESMFold2, an open‑source protein‑language‑model predictor, now offers predictions for 1 billion structures and a 6.8 billion‑sequence Atlas, delivering faster, more accurate antibody and protein‑interaction designs than AlphaFold3, while demonstrating experimental success and revealing novel CRISPR‑like proteins, though atypical cases still need careful validation.
A KAIST team used deep‑learning‑based protein structure generation and sequence design, employing an NTF2‑like fold as a universal backbone, to de novo create a library of small‑molecule binding proteins, successfully engineering a cortisol‑specific binder and converting it into an AI‑powered biosensor, with structural validation and specificity assays confirming high affinity and selectivity.
Google's Isomorphic Labs unveiled IsoDDE, dubbed AlphaFold 4, which dramatically outperforms AlphaFold 3 on hard protein‑structure benchmarks and antibody‑binding predictions, yet the model is fully closed‑source, sparking a debate about the future of open scientific AI.
The article traces Demis Hassabis’s journey from chess prodigy to DeepMind CEO, detailing the company’s transition from game‑playing breakthroughs like AlphaGo to scientific initiatives such as AlphaFold and AI4S, while examining ethical debates, Nobel‑prize controversy, and calls for global AI safety standards.
Microsoft Research’s AI for Science team released the open‑source BioEmu model, a generative diffusion architecture that leverages AlphaFold’s Evoformer and extensive MD and stability data to efficiently sample protein conformational ensembles, achieving near‑MD accuracy in free‑energy and mutation stability predictions while dramatically reducing computational cost.
In an in‑depth interview, Prof. Hong Liang of Shanghai Jiao Tong University discusses the evolution of AI for Science, the challenges of turning research breakthroughs into real‑world protein‑engineering solutions, the importance of industry‑academia collaboration, and how luck, timing, and focused problem definition drive successful AI adoption.
This article reviews the evolution from AlphaFold 2 to AlphaFold 3, introduces Baidu's HelixFold 3 as the first domestic model matching AlphaFold 3, compares their benchmark results on small‑molecule ligands, nucleic acids and protein complexes, and explains the cloud‑based service and confidence scoring that make high‑throughput structure prediction accessible.
AlphaFold 3, released by DeepMind in May 2024, dramatically speeds protein and biomolecule structure prediction, prompting predictions of a future Nobel Prize, while China’s HelixFold 3, the first domestic model matching AlphaFold 3’s performance, offers high‑accuracy, cloud‑based services for diverse molecular interactions and drug discovery.
The article introduces the MEGA-Protein tool, which integrates an AI‑driven MSA engine and the MindSpore framework to overcome AlphaFold 2’s limitations and achieve high‑accuracy protein structure prediction, and also announces the MSG Enterprise Tour and Hangzhou Developer Day event on April 27.
